

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

NOVO NORDISK A/S,

Patent Owner.

Case No. IPR2023-00722

Patent No. 8,536,122

**DECLARATION OF PETER FLATT, PH.D., IN SUPPORT OF PETITION
FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 8,536,122**

TABLE OF CONTENTS

| | Page |
|---|------|
| I. Introduction | 10 |
| II. Qualifications and Background..... | 10 |
| A. Education and Experience; Prior Testimony | 10 |
| B. Legal Standards and Materials Reviewed..... | 14 |
| C. Scope of Work | 17 |
| III. Person of Ordinary Skill in the Art..... | 17 |
| IV. The '122 Patent | 20 |
| V. Claim Construction | 25 |
| VI. Summary of Opinions | 25 |
| VII. Background on Diabetes, the Treatment of Diabetes, and GLP-1 Analogues..... | 28 |
| A. Diabetes | 28 |
| B. The Treatment of Diabetes..... | 28 |
| 1. Insulin..... | 29 |
| 2. Biguanides..... | 29 |
| 3. Sulfonylureas | 30 |
| 4. Thiazolidinediones..... | 31 |
| 5. α -Glucosidase Inhibitors and Meglitinides..... | 31 |
| 6. DPP-4 and PDE3 Inhibitors..... | 32 |
| 7. The Rise of GLP-1 Based Drugs..... | 33 |
| C. Peptides and GLP-1 Analogues..... | 37 |
| 1. General Peptide Chemistry..... | 37 |
| 2. GLP-1 Peptides | 39 |
| 3. Designing GLP-1 Analogues..... | 43 |
| 4. Liraglutide..... | 53 |
| 5. Semaglutide | 55 |
| VIII. The Challenged Claims of the '122 Patent Are Unpatentable As Obvious Under 35 U.S.C. § 103..... | 63 |

TABLE OF CONTENTS
(continued)

| | Page |
|--|-------------|
| A. Scope and Content of the Prior Art..... | 63 |
| 1. Bridon (Ex. 1014)..... | 64 |
| 2. Dong (Ex. 1013)..... | 65 |
| 3. Knudsen 2001 (Ex. 1011) | 66 |
| 4. Knudsen 2004 (Ex. 1010) | 69 |
| 5. Knudsen Patent (Ex. 1012)..... | 71 |
| 6. Additional Prior Art References and Knowledge..... | 75 |
| B. Ground 1: The Challenged Claims of the '122 Patent Would Have Been Obvious Over Knudsen 2004 in View of the Knudsen Patent, Dong, and Bridon..... | 84 |
| 1. Claims 1-2 and 4-11 of the '122 Patent | 84 |
| 2. Claim 13 of the '122 Patent..... | 126 |
| 3. Claim 15 of the '122 Patent..... | 127 |
| C. Ground 2: The Challenged Claims of the '122 Patent Would Have Been Obvious Over Knudsen 2001 in View of the Knudsen Patent, Dong, and Bridon..... | 128 |
| 1. Claims 1-2 and 4-11 of the '122 Patent | 129 |
| 2. Claim 13 of the '122 Patent..... | 142 |
| 3. Claim 15 of the '122 Patent..... | 143 |
| D. Ground 3: The Challenged Claims of the '122 Patent Would Have Been Obvious in View of Common Drug Development Principles..... | 144 |
| IX. No Secondary Considerations Overcome <i>Prima Facie</i> Obviousness of the Claimed Subject Matter..... | 148 |
| A. Semaglutide Did Not Produce Any Unexpected or Surprising Results | 149 |
| B. The Prior Art Did Not Teach Away From Semaglutide..... | 152 |
| C. There Was No Long-Felt But Unmet Need..... | 153 |
| D. There Was No Industry Skepticism | 153 |

TABLE OF CONTENTS
(continued)

| | Page |
|--|-------------|
| E. Copying by Generic Drug Makers Is Irrelevant..... | 154 |
| X. CONCLUSION..... | 154 |

TABLE OF ABBREVIATIONS

| Full Name of Cited Reference | Abbreviation |
|---|--------------|
| U.S. Patent No. 8,536,122 | '122 patent |
| U.S. Patent No. 5,512,549 | '549 patent |
| Adelhorst, <i>Structure-Activity Studies of Glucagon-like Peptide-1*</i> , 269(9) J. BIO. CHEM. 6275 (1994) | Adelhorst |
| Banting, <i>The internal secretion of the pancreas</i> , 7 J LAB CLIN MED. 251 (1922) | Banting |
| Bayliss, <i>The Mechanism of Pancreatic Secretion</i> , 28(5) J. PHYSIOLOGY 325 (1902) | Bayliss |
| Bell, <i>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides</i> , 302 NATURE 716 (1983) | Bell |
| U.S. Patent No. 6,514,500 | Bridon |
| WO 91/11457 | Buckley |
| Buse, <i>Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients with Type 2 Diabetes</i> , 27 DIABETES CARE 2628 (2004) | Buse |
| Chang, <i>The GLP-1 Derivative NN2211 Restores β-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose</i> , 52 DIABETES 1786 (2003) | Chang |
| Cistola, <i>Carbon 13 NMR Studies of Saturated Fatty Acids Bound to Bovine Serum Albumin I. The Filling of Individual Fatty Acid Binding Sites</i> , 262(23) J. BIO. CHEM. 10971 (1987) | Cistola I |
| Cistola, <i>Carbon 13 NMR Studies of Saturated Fatty Acids Bound to Bovine Serum Albumin II. Electrostatic Interactions in Individual Fatty Acid Binding Sites</i> , 262(23) J. BIO. CHEM. 10980 (1987) | Cistola II |
| Cooper, <i>Peptides as a Platform for Targeted Therapeutics for Cancer: Peptide – Drug Conjugates (PDCs)</i> , 50 CHEM. SOC. REV. 1480 (2021) | Cooper |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.